Trans-Pacific Partnership

No TPP campaign continues

November 28, 2017: The Turnbull government is trying to revive the TPP and retain many of the worst US-initiated clauses. The TPP-11 leaders have not met their deadline to finalise the text, but at the latest round of negotiations they salvaged a possible deal. The agreement has been rebranded the ' Comprehensive and Progressive TPP', and some of its most controversial clauses have been suspended, pending the US rejoining the agreement. The negotiations will continue in 2018.

New study shows TPP could cost PBS hundreds of millions

November 9, 2017: new paper by leading health experts published in the Australian Health Review and summarised in Fairfax news and The Conversation has found that the Trans-Pacific Partnership agreement could add up to $367 million to the cost of the Pharmaceutical Benefits Scheme if increases in data protection monopolies for biologic medicines proposed in the original TPP text are implemented.

Community groups oppose ISDS in TPP-11 talks as US dumps ISDS in NAFTA, and NZ also says no

November 6, 2017 “The Australian Government should oppose foreign investor rights to sue governments in the talks attempting to resurrect the TPP without the US later this week,” AFTINET Convener Dr Patricia Ranald said today.

The talks will take place in da Nang, Vietnam on November 8-9, ahead of the APEC meeting to be held on November 10.

TPP-11 still not agreed ahead of APEC deadline next week

November 2, 2017: Media reports from the secret TPP–11 meeting held in Japan this week show that there is still no agreement between the 11 governments about the possible content of the TPP agreement without the US. They were aiming to reach agreement before a TPP -11 Ministers’ meeting on November 8-9, ahead of the APEC meeting in Vietnam on November 10.

New paper explains TPP's impact on access to medicines in member countries

November 2, 2017: A new research paper, co-authored by public health experts Deborah Gleeson, Joel Lexchin, Ruth Lopert and Burcu Kilic, explains the impact that the intellectual property chapter of the original Trans-Pacific Partnership could have on access to medicines in each of the TPP countries. As the TPP-11 meet this week to attempt to revive the TPP without the US, the research findings show how damaging the original medicine proposals would be.

Pages